API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

2

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Mundipharma

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Orphan Drug Designation Granted to Mundipharma's Tinostamustine in EU for Very Rare form of Leukaemia

Details:

Tinostamustine is in early phase clinical trials (Phase I) to investigate its use as a potential future treatment option in this area of significant unmet patient need.Tinostamustine is the only medicinal product with an orphan drug designation for T-PLL in the EU.

Lead Product(s): Tinostamustine

Therapeutic Area: Oncology Product Name: EDO-S101

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2020

ASK
US